poisar

Stock

Spyre Therapeutics, Inc. SYRE

$94.04+0.33%

Overview

SYRE market data

Price History

SYRE price chart · 1M
O
91.93
H
94.74
L
91.93
C
94.04
Vol
37,646.00
Source
US equities market feed
Observed
Aug 27, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$91.93
Previous Close
$93.74
Day High
$94.74
Day Low
$91.93
52 Week High
$110.14
52 Week Low
$64.75
7 Day Return
-12.78%
30 Day Return
-5.96%
90 Day Return
+27.96%
1 Year Return
+30.94%
Daily Notional Volume
$3.5M
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$2.42
Diluted earnings per share over the trailing twelve months.
Beta
3.06
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-22,158.5%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$14.51 – $110.18
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $9B · P/B 3.55 · P/S 7,296.20.

Company News

10 captured
Deutsche Bank Maintains Buy on Spyre Therapeutics, Lowers Price Target to $127Benzinga · Aug 26, 2026, 6:01 PM
Spyre Therapeutics Says Rheumatoid Arthritis Program Misses Internal Benchmark, Stock TumblesBenzinga · Aug 26, 2026, 2:46 PM
Wedbush Maintains Outperform on Spyre Therapeutics, Lowers Price Target to $123Benzinga · Aug 26, 2026, 12:38 PM
Intuit, Zoom, Qfin Holdings And Other Big Stocks Moving Lower In Wednesday’s Pre-Market SessionBenzinga · Aug 26, 2026, 12:01 PM
Spyre Therapeutics shares are trading lower after the company announced topline results from the RA sub-study of its Phase 2 SKYWAY basket trial evaluating SPY072 in rheumatic diseases. The results did not meet the company's internal bar to prioritize advancement of SPY072 in RA.Benzinga · Aug 26, 2026, 11:47 AM
BTIG Maintains Buy on Spyre Therapeutics, Lowers Price Target to $121Benzinga · Aug 26, 2026, 10:01 AM
Why JOYY Shares Are Trading Higher; Here Are 20 Stocks Moving PremarketBenzinga · Aug 26, 2026, 9:22 AM
8-K filing — Spyre Therapeutics, Inc. (SYRE)SEC EDGAR · Aug 25, 2026, 8:04 PM
Spyre Therapeutics Says Both Doses Of SPY072 Met Statistical Significance On One Or More Endpoints In Phase 2 SKYWAY Rheumatoid Arthritis Sub-Study; Says Effect Did Not Meet Its Bar To Prioritize Monotherapy Development In RABenzinga · Aug 25, 2026, 8:02 PM
Target To Rally Around 12%? Here Are 10 Top Analyst Forecasts For TuesdayBenzinga · Aug 11, 2026, 11:59 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock